Countries throughout the world are facing a growing non-communicable disease (NCD) burden. In developing countries, medicines to treat NCDs are often difficult to access or too expensive for many households. Novartis/Sandoz has recently launched Novartis Access, an initiative to subsidize a basket of NCD medicines sold to purchasers in program countries and delivered through the public and non-profit health sectors. This study will evaluate the impact of Novartis Access on the availability and price of NCD medicines at health facilities and households in Kenya, the first country to receive the program.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Availability of Novartis Access medicines and equivalents at public and private non-profit facilities: proportion of Novartis Access NCD medicines and equivalents that a facility has in stock on the day of data collection
Timeframe: One year
Price of Novartis Access medicines and equivalents at public private non-profit facilities
Timeframe: One year
Availability of Novartis Access medicines and equivalents at alternative for-profit drug sellers: proportion of Novartis Access NCD medicines and equivalents in stock on the day of data collection
Timeframe: One year
Availability of Novartis Access medicines and equivalents in households with NCD patients: proportion of prescribed Novartis Access medicines and equivalents in the home on the day of data collection
Timeframe: One year
Price per unit for Novartis Access medicines and equivalents in households with NCD patients
Timeframe: One year
Expenditure on Novartis Access medicines and equivalents in households with NCD patients
Timeframe: One year
Price of Novartis Access medicines and equivalents at alternative for-profit drug sellers
Timeframe: One year